FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2245864725> ?p ?o ?g. }

• W2245864725 endingPage "7515" @default.
• W2245864725 startingPage "7515" @default.
• W2245864725 abstract "7515 Background: Metastatic melanoma remains a highly chemotherapy-resistant disease, for which there is no cure. One of the few recent advances in treating metastatic melanoma is the addition of Bcl-2 antisense to dacarbazine as first line therapy, which increases response rates, median survival and disease free survival. Studies in the literature report a very wide range of frequencies of expression of the anti-apoptotic protein Bcl-2 in melanoma specimens (60% to 96%). Some reports have shown up regulation of Bcl-2 with increased disease aggression, while other groups have demonstrated an inverse relationship. These studies have included fewer than 100 patients; therefore we sought to re-address this issue using a large cohort of melanoma specimens. Methods: Tissue microarrays containing specimens from 282 melanoma patients with 20 year follow-up were employed and evaluated with our AQUA system for automated quantitative analysis. The system uses S100 to define pixels as melanoma (tumor mask) within the array spot, and then measures intensity of Bcl-2 expression using Cy5 conjugated antibodies within the mask. Scores were divided into quartiles, and correlated with clinical and pathological variables. Results: High Bcl-2 expression was associated with better outcome in the entire cohort and among the metastatic specimens only (P = 0.02 and P = 0.01, respectively). Bcl-2 expression was higher in primary than in metastatic specimens (P = 0.002) and in patients older than 50 years of age (P = 0.03). Among the primary specimens there was no association between Bcl-2 expression and Breslow depth and Clark level. Conclusions: High Bcl-2 expression is associated with better survival in melanoma and with earlier stage disease. The diverse results in the literature might be due to use of small cohorts or to variability in staining technique. Studies are needed to evaluate the association between Bcl-2 expression and response to Bcl-2 antisense. Patient selection based on Bcl-2 expression might improve response rates to Bcl-2 antisense. No significant financial relationships to disclose." @default.
• W2245864725 created "2016-06-24" @default.
• W2245864725 creator A5001175430 @default.
• W2245864725 creator A5016052019 @default.
• W2245864725 creator A5057160792 @default.
• W2245864725 creator A5061144291 @default.
• W2245864725 creator A5084659842 @default.
• W2245864725 creator A5085976734 @default.
• W2245864725 date "2004-07-15" @default.
• W2245864725 modified "2023-10-16" @default.
• W2245864725 title "Evaluation of Bcl-2 expression in melanoma - A tissue microarray study" @default.
• W2245864725 doi "https://doi.org/10.1200/jco.2004.22.90140.7515" @default.
• W2245864725 hasPublicationYear "2004" @default.
• W2245864725 type Work @default.
• W2245864725 sameAs 2245864725 @default.
• W2245864725 citedByCount "0" @default.
• W2245864725 crossrefType "journal-article" @default.
• W2245864725 hasAuthorship W2245864725A5001175430 @default.
• W2245864725 hasAuthorship W2245864725A5016052019 @default.
• W2245864725 hasAuthorship W2245864725A5057160792 @default.
• W2245864725 hasAuthorship W2245864725A5061144291 @default.
• W2245864725 hasAuthorship W2245864725A5084659842 @default.
• W2245864725 hasAuthorship W2245864725A5085976734 @default.
• W2245864725 hasConcept C126322002 @default.
• W2245864725 hasConcept C142724271 @default.
• W2245864725 hasConcept C143998085 @default.
• W2245864725 hasConcept C193270364 @default.
• W2245864725 hasConcept C204232928 @default.
• W2245864725 hasConcept C2777658100 @default.
• W2245864725 hasConcept C2780964509 @default.
• W2245864725 hasConcept C502942594 @default.
• W2245864725 hasConcept C71924100 @default.
• W2245864725 hasConceptScore W2245864725C126322002 @default.
• W2245864725 hasConceptScore W2245864725C142724271 @default.
• W2245864725 hasConceptScore W2245864725C143998085 @default.
• W2245864725 hasConceptScore W2245864725C193270364 @default.
• W2245864725 hasConceptScore W2245864725C204232928 @default.
• W2245864725 hasConceptScore W2245864725C2777658100 @default.
• W2245864725 hasConceptScore W2245864725C2780964509 @default.
• W2245864725 hasConceptScore W2245864725C502942594 @default.
• W2245864725 hasConceptScore W2245864725C71924100 @default.
• W2245864725 hasIssue "14_suppl" @default.
• W2245864725 hasLocation W22458647251 @default.
• W2245864725 hasOpenAccess W2245864725 @default.
• W2245864725 hasPrimaryLocation W22458647251 @default.
• W2245864725 hasRelatedWork W1982580546 @default.
• W2245864725 hasRelatedWork W2057024276 @default.
• W2245864725 hasRelatedWork W2081153887 @default.
• W2245864725 hasRelatedWork W2082088498 @default.
• W2245864725 hasRelatedWork W2145585841 @default.
• W2245864725 hasRelatedWork W2460490427 @default.
• W2245864725 hasRelatedWork W2587188871 @default.
• W2245864725 hasRelatedWork W2740405643 @default.
• W2245864725 hasRelatedWork W3139091425 @default.
• W2245864725 hasRelatedWork W4249253137 @default.
• W2245864725 hasVolume "22" @default.
• W2245864725 isParatext "false" @default.
• W2245864725 isRetracted "false" @default.
• W2245864725 magId "2245864725" @default.
• W2245864725 workType "article" @default.